VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow

Autor: David R. Light, Sharada A. Sarnaik, Moira M. Lancelot, Nancy Moore, Dipti Gupta, Patrick C. Hines, William E. Hobbs, Jennell White, Sriram Krishnamoorthy

Publikováno v: British Journal of Haematology. 174:970-982

Summary Very Late Antigen-4 (VLA-4, α4β1-integrin, ITGA4) orchestrates cell-cell and cell-endothelium adhesion. Given the proposed role of VLA-4 in sickle cell disease (SCD) pathophysiology, we evaluated the ability of the VLA-4 blocking antibody n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c18a3818ea8ce196fff64f784758774
https://doi.org/10.1111/bjh.14158

Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay

Autor: Moira M. Lancelot, Patrick C. Hines, Sharada A. Sarnaik, Jennell White

Publikováno v: British Journal of Haematology. 178:479-481

Keywords: erythrocytes; adhesion; VLA-4; sickle cell disease; low molecular weight heparin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a1db9b3c6ce8af5b6ed36eb6088b2db
https://doi.org/10.1111/bjh.14137

Natalizumab Blocks VLA-4 Mediated Red Blood Cell Adhesion and Is a Potential Therapy for Sickle Cell Disease

Autor: Sriram Krishnamoorthy, William E. Hobbs, David R. Light, Patrick C. Hines, Moira M. Lancelot, Arjan van der Flier, Haiyan Jiang, Dipti Gupta, Jennell White, Robert T. Peters

Publikováno v: Blood. 124:221-221

Sickle cell disease (SCD) is caused by a point mutation in the beta-chain of hemoglobin, which triggers a complex pathophysiology resulting in recurrent, painful vaso-occlusive events (VOCs) and chronic hemolytic anemia. Among other abnormalities, si

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::026ef9043151b8a3b3be46ef6cbca45a
https://doi.org/10.1182/blood.v124.21.221.221

VLA-4 Blockade by Low Molecular Weight Heparin: A Novel Therapeutic Approach in Sickle Cell Disease

Autor: Moira M. Lancelot, Sharada A. Sarnaik, Jennell White, Patrick C. Hines

Publikováno v: Blood. 120:2113-2113

Abstract 2113 Background and Significance Vaso-occlusion in sickle cell disease (SCD) that leads to painful events and complications is caused in part by adhesion of sickled erythrocytes (SSRBCs) to components of the vascular wall and to circulating

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::52571816579420a6e5db4b916cbacfc4
https://doi.org/10.1182/blood.v120.21.2113.2113

Effect of swab pooling on the Accula point-of-care RT-PCR for SARS-CoV-2 detection.

Autor: Lancelot M; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States., Fibben K; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, United States., Sullivan J; The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies, Atlanta, GA, United States.; Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, United States., O'Sick W; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States., McLendon K; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States., Wu H; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States., Rao A; The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies, Atlanta, GA, United States.; Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, United States., Bassit LC; The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies, Atlanta, GA, United States.; Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, United States.; Laboratory of Biochemical Pharmacology, Emory University, Atlanta, GA, United States., Greenleaf M; The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies, Atlanta, GA, United States., Miller P; Rapid Acceleration of Diagnostics (RADx), Maryland, MD, United States., Krull W; Rapid Acceleration of Diagnostics (RADx), Maryland, MD, United States., Tyburski E; The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies, Atlanta, GA, United States., Roback JD; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States., Lam WA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, United States.; The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies, Atlanta, GA, United States.; Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, United States.; Aflac Cancer & Blood Disorders Center at Children's Healthcare of Atlanta, Atlanta, GA, United States., Damhorst GL; The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies, Atlanta, GA, United States.; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States.

Publikováno v: Frontiers in microbiology [Front Microbiol] 2023 Aug 07; Vol. 14, pp. 1219214. Date of Electronic Publication: 2023 Aug 07 (Print Publication: 2023).